Metformin Shows Promise as Anti-Aging Drug Beyond Diabetes Treatment
Research reveals how the diabetes drug metformin may extend lifespan and healthspan through multiple molecular pathways.
20 articles
Research reveals how the diabetes drug metformin may extend lifespan and healthspan through multiple molecular pathways.
A 2025 review reveals how metformin's AMPK activation and mitochondrial effects may slow aging beyond its diabetes role.
A major review challenges the evidence behind metformin as a longevity drug, exposing methodological flaws in landmark studies.
New review maps metformin's complex pathways beyond diabetes, showing how it targets cancer and aging through AMPK, mTOR, and mitochondrial mechanisms.
New study reveals metformin's anti-aging effects depend entirely on whether you're insulin resistant or sensitive.
A 2025 review reveals metformin's multi-pathway potential to slow arterial aging, reduce stiffness, and protect the heart.
Wake Forest study explores whether the diabetes drug metformin can trigger cellular changes linked to longevity in healthy people.
A comprehensive review reveals metformin's polypharmacological mechanisms—from AMPK activation to gut microbiome remodeling—that may delay aging and enhance cancer immunotherapy.
A 2025 review reveals metformin's promising dermatological applications—from acne and psoriasis to wound healing and anti-aging effects.
Major trial tests whether diabetes drug metformin can prevent frailty syndrome that affects millions of aging adults.
Large randomized trial finds metformin doesn't slow placental aging, challenging its potential as anti-aging therapy during pregnancy.
New research reveals metformin's complex effects on aging - protecting frail adults while potentially limiting muscle gains in active individuals.
A sweeping 2025 review traces metformin from its 1922 synthesis to its emerging roles in cancer, aging, and longevity.
Six-month trial examines whether metformin treatment can improve telomere length and longevity gene expression in prediabetic individuals.
Clinical trial tested whether metformin could improve surgical outcomes and reduce hospital stays in non-diabetic older patients.
Environmental factors in lab media can completely block metformin's lifespan benefits, while phenformin remains effective.
Columbia University tested whether the diabetes drug metformin could slow memory loss in people with mild cognitive impairment.
Novel drug delivery system combines metformin with bioactive compounds to combat bone aging and improve fracture repair in elderly patients.
A 1.6-million-person cohort study finds metformin neither prevents AMD development nor slows progression to advanced disease stages.
A 2025 narrative review examines metformin's benefits, risks, and sex-specific efficacy for prediabetic women navigating the menopausal transition.